Xin Jiang

Signosis Inc. is a molecular tools company focused on enabling biomarker discovery and drug development through innovative plate‑based assays and stable reporter cell lines. Founded in 2007 and headquartered in Santa Clara, California, Signosis combines in‑house R&D, manufacturing, and strict QC to deliver sensitive, rapid, and affordable platforms for analyzing disease‑related proteins, nucleic acids, transcription factors, and signaling pathways. ​ The product portfolio spans cytokine and hormone ELISAs, TF profiling arrays and EMSAs, luciferase reporter vectors, oxidative stress and disease biomarker combo kits, and more than 80 TF reporter and receptor‑based stable cell lines, including models for RTKs and GPCRs such as EGFR, HER2, FLT3 mutants, GLP‑1R, and GIPR. Custom assay development and stable cell line services extend these platforms to customer‑defined pathways and targets, supporting applications from pathway mapping and compound screening to translational biomarker validation. ​ By integrating biochemistry, genomics, and cell‑based assay expertise, Signosis helps researchers worldwide convert complex biosignals into clear, mechanism‑linked evidence that advances next‑generation diagnostics and therapeutics